Indacaterol vs long‐acting beta2‐agonist alone: Serious adverse events Adverse events
Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Indacaterol vs twice‐daily long‐acting beta2‐agonists Serious adverse events Adverse events · patients with chronic obstructive pulmonary disease Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty). Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic… (2015) · Cochrane Headline outcomes only | OR 1.02 [0.79, 1.32] | 4 studies · 3266 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive pulmonary disease 2015 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.